Relation between BCL-2 oncoprotein expression and some prognostic factors in papillary thyroid carcinoma

Abstract

Background and Objective: Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy. Expression of BCL-2, an apoptosis inhibitor, is higher in papillary thyroid carcinoma cells. Prognosis of PTC is associated with some factors such as age, gender, tumor size, capsular invasion and lymph node involvement. The aim of this study was to demonstrate relation between BCL-2 oncoprotein expression and these prognostic factors in PTC.


Materials and Methods: In this cross-sectional study, 85 pathology samples of PTC patients were analyzed for capsular invasion and BCL-2 oncoprotein expression by immunohistochemistry method. Other data such as age, gender, tumor size and lymph node involvement were collected from clinical records of patients. Data were analyzed by SPSS.


Results: The mean age was 40.8 ±16.4 years (75 females and 10 males). The mean tumor size was 3.7±2.2 cm. Meanwhile, 11 samples had capsular invasion and the others were negative. Lymph node involvement was positive in 19 samples (22.3%). The BCL-2 expression was positive in 71 samples (87.1 %). There was no significant relation between BCL-2 expression and lymph node involvement and capsular invasion. A significant relation was seen between tumor size and BCL-2 expression. BCL-2 expression was associated with a larger tumor size.


Conclusion: BCL-2 expression in PTC patients was high and has relation with tumor size. Lymph node involvement and capsular invasion have not any relation with BCL-2 expression.

Keywords

References

1. Mohagheghi M, Moosavi JA, Shariat TS: Annual report of Tehran University of Medical Sciences, District cancer registry in 1997. 2. Hrafnkelsson J, Tulinius H, Sigvaldson H. Familial nonmedullary thyroid cancer in Iceland. Journal of Medical Genetic 2001;38:189-91. 3. Drake RL, Vogl W, itchell AWM, ray H. Gray's anatomy for students. 2nd ed. Philadelphia: Churchill Livingstone/Elsevier; 2014. 4. Deandrea M, Gallone G, Veglio M. Thyroid cancer hystotype changes as observed in a major generalHospital in a 21 year period. Journal of Endocrinology Investigation 1997; 20:52-8. 5. Rosai J, Tallini G. Rosai and Ackerman's surgicalpathology. 10th ed. New York: Mosby; 2011. 6. Choi D, Hwang S, Lee E. Expression of mitochondria dependent apoptosis genes (p53, Bax, Bcl-2) in rat granulosa cells during follicular development. Journal of the Society for Gynecologic Investigation 2004; 11:311-7. 7. Mitsiades N, Poulaki V, Kotoula V, Mastorakos G, Tseleni-Balafouta S, Koutras DA, et al. Fas/Fas ligand up-regulation and Bcl-2 downregulation may be significant in the pathogenesis of Hashimoto’s thyroiditis. The Journal of Clinical Endocrinology & Metabplism. 1998: 83:2199–203. 8. Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G. Novel histone deacetylase inhibitors in the treatment of thyroid cancer. Clinical Cancer Research. 2005: 11:3958–65. 9. Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S. Expression of bcl-2 in Papillary Thyroid Cancers and its Prognostic Value. Actachirbelg 2005; 105: 644-8. 10. Dinets A, Hulchiy M, Sofiadis A, Ghaderi M, Höög A, Larsson C, etal. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma. European Journal of Endocrinology. 2012;166(6):1049-60. 11. Longo D L, Fauci AS, Kasper DL, Hauser StL, Jameson JL ,Loscalzo J. Harrison's principles of internal medicine. 18thed, New York: McGraw hill; 2012. 12. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di LibertoD,Patti M, etal. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Research. 2003; 63(20):6784-90. 13. Siironen P, Nordling S, Louhimo J, Haapiainen R, Haglund C.Immunohistochemical expression of Bcl-2, Ki-67, and p21 in patients with papillary thyroid cancer. Tumour Biology. 2005 ; 26(1):50-6. 14. Manetto V, Lorenzini R, Cordon-Cardo C, Krajewski S, Rosai J, Reed JC, et al. Bcl-2 and Bax expression in thyroid tumours. An immunohistochemical and western blot analysis. Virchows Archives. 1997; 430(2):125-30. 15. Aksoy M, Giles Y, Kapran Y, Terzioglu T, Tezelman S. Expression of bcl-2 in papillary thyroid cancers and its prognostic value. Acta Chirurgica Belgica. 2005; 105(6):644-8. 16. Soda G, Antonaci A, Bosco D, Nardoni S, Melis M. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas. Journal of Experimental & Clinical Cancer Research 1999; 18(3):363-7.
Daneshvar Medicine
Volume 25, Issue 1 - Serial Number 128
March and April 2017
Pages 1-4

Files

Share

How to cite

Statistics